ArticleFrontiers in medicine2025
Compare the prognosis of pancreatic cancer patients with different treatment modalities and use machine learning methods to build predictive models.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) is highly refractory to most treatments. Multimodal treatment, combining several types of therapies, is likely to benefit PC patients. However, it remains unclear which multimodal treatment is most effective and how to predict outcomes from different combinations. This study compared overall survival among PC patients receiving chemotherapy alone (C), immunotherapy combined with chemotherapy (CI), radiotherapy combined with chemotherapy (CR), and triple-combination therapy (CRI). A machine learning-based predictive model between monomodal and multimodal therapy was established using 3 years of clinical follow-up data. Methods: We retrospectively analyzed 125 cases of PC patients treated at Yixing People's Hospital from January 2014 to June 2024 (C, Results: Multimodal treatments significantly improved PC prognosis ( Conclusion: PC patients may benefit from more intensive multimodal therapies, which provides novel insights into predicting PC survival prognosis and highlights the potential of machine learning in biomarker identification and disease prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.